The Diagnostic Value of Anti-Mullerian Hormone Marker in Predicting Response to Treatment of Infertility in Patients with Polycystic Ovary Syndrome

This study aimed to evaluate the diagnostic value of anti-Mullerian hormone (AMH) marker in predicting response to treatment of infertility in patients with polycystic ovary syndrome (PCOS).
This study was conducted on 80 patients with PCOS who were candidates for infertility treatment. In all patients, the serum levels of AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone and estradiol were measured in the 3rd day of menstrual cycle; then were treated using clomiphene. For the patient who responded to clomiphene, human menopausal gonadotropin (HMG) was added. Then, in the patient with follicle of size of 17 mm, human corionic gonadotropin (HCG) was administered followed by intercourse after 36 hours. After 14 days from HCG injection, βhCG was measured. In patients with positive βhCG, transvaginal sonography was done after 2 weeks. The relationship between serum level of AMH and pregnancy rate were assessed. P value of more than 0.05 was concedered as significant.
Findings: Cut-of-point for AMH level according to presence or absence of pregnancy was 4.85 ng/ml and it was not statistically significant (P = 0.079).
This study shows that the serum level of AMH is not an appropriate predictor of responsing to treatment with clomiphene gonadotropin in weman with PCOS.